Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973737 | 0.82 | SCN9A (0.38) | KDM4EGAAPIM1 | |
| SCHEMBL18249554 | 0.81 | ADA (0.34) | APPPARP10PIM1 | |
| SCHEMBL18249538 | 0.80 | PARP1 (0.36) | APPALDH1A1PARP1CA1PIM1 | |
| SCHEMBL18249543 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1PIM1 | |
| SCHEMBL14955110 | 0.77 | PIM1 (0.38) | NNMTPARP1GRM2PIM1CASP1 | |
| SCHEMBL11972998 | 0.77 | PIM1 (0.38) | APPPARP1GRM2PIM1 | |
| SCHEMBL3038786 | 0.74 | KDM4E (0.35) | CYP11B1CYP11B2KDM4EHPGDSPLAU | |
| SCHEMBL6827783 | 0.74 | KDM4E (0.60) | APPCYP11B1CYP11B2KDM4EHPGDS | |
| SCHEMBL18249537 | 0.72 | KDM4E (0.45) | KDM4EALDH1A1TP53GAACA1 | |
| SCHEMBL18249535 | 0.72 | CHEK2 (0.48) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457662-B2 | Substituted amides for treating and preventing cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-10-04 | — | — | US | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | NNT, NQO1, NAMPT | APP 3642/4885NNMT 4/4885CYP11B1 3207/4885 |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | APP 1226/4885NNMT 2658/4885CYP11B1 694/4885 |
| US-10457662-B2 | Substituted amides for treating and preventing cancer | NQO1, NNT, SIRT1 | APP 4412/4885NNMT 7/4885CYP11B1 4026/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | APP 1226/4885NNMT 2658/4885CYP11B1 694/4885 |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | APP 3162/4885NNMT 372/4885CYP11B1 78/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | APP 3162/4885NNMT 372/4885CYP11B1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.